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Pellegrin, University of Medicine, Bordeaux, FranceHeparin-induced thrombocytopenia is a rare but serious complication of heparin therapy. Most of cases are related to
unfractionated heparin, but a few are due to low molecular weight heparin sometimes associated with unfractionated
heparin.
A patient with pulmonary contusions after chest injury developed a catheter related subclavian vein thrombosis on day 16.
He was treated by increasing doses of low molecular weight heparin. Aortic and renal thromboses occurred on day 21.
Surgical thrombectomy, performed after starting alternative anticoagulation treatment led to complete arterial recovery.
In case of suspicion of heparin-induced thrombocytopenia, with unfractionated or low-molecular-weight heparin, heparin
treatment must be discontinued before the results of biological tests become available. Arterial and/or venous thrombosis is a
serious complication of heparin-induced thrombocytopenia. The treatment has two aims: first, to restore arterial patency by
clot removal by thrombectomy, bypass or thrombolysis, and second, to avoid new thrombosis formation by substitutive
anticoagulation treatment: danaparoid may have cross-reaction with heparin, or lepirudin has anaphylactic risks and needs
biological follow-up.
Heparin-induced thrombocytopenia and thrombosis can be complicated by death or disabilities such as amputations, stroke,
renal or bowel infarction.
Once HIT has been diagnosed heparin should never be given again, but if cardiopulmonary bypass is required, it might be
reintroduced during operation only if serum antibodies have disappeared.Keywords: Heparin; Thrombosis; Thrombocytopenia.Introduction
Because subcutaneous low-molecular-weight heparin
is associated with a lower risk of bleeding it is
routinely recommended as a safer alternative to
intravenous heparin as a prophylactic measure against
venous thromboembolism. Unlike intravenous
heparin, it is thought to be associated with a much
lower rate of HIT.
Heparin-induced thrombocytopenia, defined as a
sudden decrease in the platelet count, usually appears
5–15 days after the start of heparin therapy.1 It maying author. Dr J. Chevalier, MD, Service de Chirurgie
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severity depends on the outcome of thrombotic
complications involving deep veins, or arteries, or
both. Since, the first case of thrombocytopenia with
arterial thrombosis during heparin therapy was
described in 1958,2 the pathophysiology of this
paradoxic phenomenon is now better understood,
and prevention as well as substitution treatments are
standardized. Although low-molecular-weight
heparin was initially proposed for the treatment of
heparin-induced thrombocytopenia,3 we report an
unusual case of a patient in whom low-molecular-
weight heparin was the cause of thrombocytopenia.
This report is instructive because it alerts the medical
community and especially vascular surgeons to a rare
but dramatic drug-induced complication that theyEur J Vasc Endovasc Surg 29, 209–212 (2005)
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more often in the future.Case Report
A 44-year-old man, with a history of smoking, fell
down the stairs and injured the lower left chest. He
suffered no visceral lesions but had rib fractures and a
pulmonary contusion. He was hospitalized in the
intensive care unit for assisted ventilation and
received anti-thrombotic prophylaxis with low-mol-
ecular-weight heparin as well as the introduction of a
radial arterial line, which was flushed through daily
with a heparin solution. On day 7, chest drainage was
needed for hemothorax and atelectasis. On day 16, a
venous peri-catheter thrombosis developed in the
subclavian vein. After removal of this catheter, therapy
with low-molecular-weight heparin, routinely pre-
scribed in the intensive care unit, was increased. The
platelet count was low (125!109/l, normal count 150–
400!109/l). On day 21, an acute lower limb ischemia
developed, and the femoral pulses almost disap-
peared. The duplex ultrasound investigation showed
indirect signs of left iliac stenosis and of right iliac
thrombosis. Over the next 7 days, the platelet count
decreased to 48!109/l (Fig. 1). The patient was
promptly transferred to our vascular surgery unit for
treatment.
Examination on arrival showed that the ischemia
had partially regressed, and the patient had only
minor neurological signs. An abdominal computed
tomographic (CT) scan with contrast injection showed
a thrombus in the aortic bifurcation and proximal iliac
arteries, as well as a thrombus involving the intrarenal
aorta segment and the origin of the right renal artery
(Fig. 2). There was no lumbar pain, and no renal
failure. A serum antiplatelet factor 4 antibody test was
positive. Heparin was therefore discontinued and
substituted with the anticoagulant danaparoid untilFig. 1. Progressive chang
Eur J Vasc Endovasc Surg Vol 29, February 2005the platelet count improved. At surgery, performed on
day 27 as ischemia was moderate, two distinctive
white clots in the intrarenal aorta and right renal artery
(Fig. 3) were removed by thrombectomy through a
medial approach after suprarenal artery clamping,
and other clots were removed from the distal aorta and
proximal iliac arteries after infrarenal clamping. The
operation proceeded without problems, and the
peripheral pulses immediately recovered. The post-
operative period was complicated by septic shock
from a pulmonary infection treated medically by
assisted ventilation and antibiotic therapy. A post-
operative duplex ultrasound follow-up scan revealed
patent aortic, iliac, lower limb and renal arteries. After
the infection resolved the postoperative period was
uneventful and the patient was discharged. A 6-month
course of anticoagulant treatment with fluindione was
prescribed. Six months after the initial event, the
patient was asymptomatic and the follow-up duplex
ultrasound examination yielded normal findings.Discussion
The patient we describe received low-molecular-
weight heparin for anti-thrombotic prophylaxis after
a chest injury followed by an increased dose for
catheter-related thrombosis. Arterial thrombosis
related to low-molecular-weight heparin has been
described in only a few cases.4–9 In a report of
prospective studies of surgical patients, heparin-
induced thrombocytopenia developed in 2/1288
patients prescribed low-molecular-weight heparin
and in 54/1597 prescribed unfractionated heparin.10
None of the reported cases of heparin-induced
thrombocytopenia were associated with clinical
thrombosis. In retrospective cohort studies of
heparin-induced thrombocytopenia, an associated
thrombosis was noted in 7–97% of cases, and the
ratio of venous to arterial thrombosis was 0.6–4.3.10es in the platelet count.
Fig. 2. CT scan showing intrarenal aortic thrombosis extending to the right renal artery.
HIT and Aortic Thrombosis 211In this case, thrombocytopenia developed 15 days
after the patient received heparin. Heparin-induced
thrombocytopenia typically appears from 5 to 21 days
after the beginning of heparin treatment, unless
heparin has been given for any reason in the preceding
100 days.11 Heparin-induced thrombocytopenia may
develop up to 40 days later after treatment with low-
molecular-weight heparin than after treatment withFig. 3. Figure showing ‘White Clot’ of fibrin and platelets
removed from the aorta.unfractionated heparin.12 Our patient’s clinical
records make no mention of serum tests for heparin-
dependent IgG antibodies. The frequency of heparin-
dependent IgG antibodies is reportedly higher in
patients receiving unfractionated heparin than in
patients receiving low-molecular-weight heparin.11
As the acute aortic and renal thrombosis in our
patient underlines, aortic thrombosis in heparin-
induced thrombocytopenia may involve any arterial
segment from the aortic arch to the bifurcation and any
collateral branches.13–15 Arterial thrombosis due to
heparin-induced thrombocytopenia may be associated
with deep-vein thrombosis, as in our case.16
In our patient the diagnosis of heparin-induced
thrombocytopenia was confirmed by a positive
response to antiplatelet factor 4 antibody. The cur-
rently recommended laboratory tests for biological
confirmation are an immune test for antiplatelet factor
4 antibodies and a platelet activation test.
In patients who present with heparin-induced
thrombocytopenia accompanied by acute arterial
thrombosis, treatment has two aims: to resolve the
associated arterial or venous thrombosis (surgically in
our case) and at the same time prevent it from
spreading. After heparin injections stop, thrombosis
can be prevented with danaparoid sodium, but in 5%
of the cases thrombosis worsens because of cross-
reactions. Although lepirudin, proposed as a cure for
thrombotic diseases, induces no cross-reactions it has
an anaphylactic risk, and a risk of bleeding that
necessitates regular laboratory tests to check the
activated partial thromboplastin time.16 Warfarin
anticoagulation is not recommended during acute
thrombocytopenia in patients with heparin-induced
thrombocytopenia associated with deep-vein throm-
bosis because it can lead to venous limb gangrene.11
These venous limb gangrene correlate with a highEur J Vasc Endovasc Surg Vol 29, February 2005
J. Chevalier et al.212international normalized ratio, persistent in vivo
thrombin generation and reduced protein C activity.18
Oral anticoagulation must be delayed until the platelet
count returns to at least 100!109 and the risk of
bleeding is controlled.
As it did in our patient, aortic thrombosis within the
intrarenal aorta and extending to the iliac arteries, a
rare complication known as the white clot syndrome,
generally responds to surgical thrombectomy,19 with
or without bypass.14 Some patients have been success-
fully treated by thrombolysis with urokinase, or
streptokinase.15 Our patient could not be treated
with thrombolytic agents because of his recent thoracic
injuries and treatment.
Despite the diagnostic delay, after surgery our
patient not only survived but also suffered no late
complications. The reported prognosis of heparin-
induced thrombocytopenia in association with arterial
thrombosis is poor and may reach 50% morbidity and
25%mortality.16 Morbidity includes limb amputations,
stroke with neurological disability, and bowel or renal
infarction.
All patients who have had an episode of HIT must
carry a warning card alerting hospital staff to their
immune sensitivity to heparin. Should patients who
have suffered heparin-induced thrombocytopenia
with deep-vein or arterial thrombosis later need
cardiac surgery with a cardiopulmonary bypass, they
can receive heparin injections again provided that
serum antibodies have disappeared.17
In conclusion, thrombocytopenia is an exceptional
complication after therapy with low-molecular-weight
heparin. The thrombotic lesions may nevertheless be
as severe as the better known lesions caused by
unfractionated heparin. To avoid disability or death,
heparin should be discontinued and substituted with
an alternate anticoagulant with appropriate surgical
therapy or thrombolysis undertaken without delay.Acknowledgements
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